Targeting Trypanosoma cruzi Platelet-activating Factor Receptors: Scope for the Development of Novel Drugs to Treat Chagas Disease

Author(s): Daniel Fábio Kawano, Ivone Carvalho

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 13 , Issue 7 , 2013

Become EABM
Become Reviewer
Call for Editor


Chagas Disease (CD), a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, accounts for the highest burden of parasitic diseases in the Western hemisphere. Current drug treatments for CD are highly toxic and often ineffective, particularly for the chronic stage of the disease, a fact that clearly emphasizes the importance of identification/validation of molecular targets for the development of new drugs to treat the disease. Here, we review in details the evidences that suggest the existence of specific receptors for platelet-activating factor (PAF) in T. cruzi, the role of PAF on the control of parasite differentiation and the potential of exploring these putative receptors as new targets for the chemotherapy of CD.

Keywords: Chagas disease, G-protein coupled receptors, phospholipids, platelet-activating factor, PAF receptors, Trypanosoma cruzi.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 March, 2013
Page: [997 - 1004]
Pages: 8
DOI: 10.2174/1389557511313070005
Price: $65

Article Metrics

PDF: 7